Dalai Yan
5 Papers
85 Citations
Dalai Yan is an academic researcher. The author has contributed to research in topics: Rifamycin & Staphylococcus aureus. The author has an hindex of 5, co-authored 5 publications.
Chat about Author
Papers
In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.
Gregory T. Robertson,Eric J. Bonventre,Timothy B Doyle,Qun Du,Leonard R. Duncan,Timothy W. Morris,Eric D. Roche,Dalai Yan,A. Simon Lynch +8 more
TL;DR: In this paper, the authors describe mode-of-action studies with Staphylococcus aureus of CBR-2092, a novel hybrid that combines the rifamycin SV and 4H-4-oxo-quinolizine pharmacophores.
74
In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Microbiology Profiling Studies with Staphylococci and Streptococci
Gregory T. Robertson,Eric J. Bonventre,Timothy B Doyle,Qun Du,Leonard R. Duncan,Timothy W. Morris,Eric D. Roche,Dalai Yan,A. Simon Lynch +8 more
TL;DR: Overall, CBR-2092 exhibited promising activity in a range of antimicrobial assays performed in vitro that pertain to properties relevant to the effective treatment of serious infections mediated by gram-positive cocci.
64
Preparation and in vitro anti-staphylococcal activity of novel 11-deoxy-11-hydroxyiminorifamycins.
TL;DR: The preparation and anti-staphylococcal activity of a series of novel 11-deoxy-11-hydroxyiminorifamycins exhibit potent activity against wild-type Staphylitis aureus with MICs equivalent to, or better than, rifamycin reference agents.
15
Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins.
In Ho Kim,Keith D. Combrink,Zhenkun Ma,Katrina Chapo,Dalai Yan,Paul J. Renick,Timothy W. Morris,Mark Pulse,Jerry W. Simecka,Charles Z. Ding +9 more
TL;DR: A novel series of spirorifamycins shows excellent activity against Staphylococcus aureus that is equivalent to rifabutin, however, some compounds of the series exhibit lower MICs than rifAButin against rifampin-resistant strains of S. aUREus.
13
New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases
Keith D. Combrink,Daniel Denton,Susan Harran,Zhenkun Ma,Katrina Chapo,Dalai Yan,Eric J. Bonventre,Eric D. Roche,Timothy B Doyle,Gregory T. Robertson,Anthony Simon Lynch +10 more
TL;DR: A novel series of 3-morpholino rifamycins in which the C25 acetate group was replaced by a carbamate group were prepared and found to exhibit significantly improved antimicrobial activity than rifampin against Mycobacterium smegmatis.